Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids?
B Robinzon and M Cutolo Department of Animal Science, Faculty of Agricultural, Food and Environmental Quality Sciences, The Hebrew University of Jerusalem, Rehovot, Israel. Adrenocorticotrophic hormone (ACTH) induces the concomitant secretion of glucocorticoids (GC) and dehydroepiandrosterone (DHEA) from the adrenal cortex. Whereas GC are catabolic, DHEA is anabolic. Long-term GC administration may result in some deleterious side-effects, such as muscular weakness, atrophy and necrosis, diabetes, fattiness, osteopenia, osteoporosis and avascular necrosis and susceptibility to infections. DHEA ameliorates some deleterious effects of GC, such as diabetes, amino acid deamination, fattiness, hypertension and susceptibility to viraemia. By its anabolic effects in muscles, bones and endothelium, DHEA may diminish the severity of GC-induced myopathy, osteopenia, osteoporosis and avascular necrosis. The natural concomitant secretion of DHEA with GC probably enables the latter to protect the bo
Related Questions
- My doctor suggested I use Hormone Replacement Therapy (HRT) but I don’t like the idea of being on a medication with a long list of side effects. What are my options?
- Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids?
- Does hormone replacement therapy contribute to the recurrence of brain tumors?
